Drug design

Small molecule drug candidates against CNS diseases. MolCode researchers have identified efficient small molecule antagonists for binding to the D2 receptor and short peptide neurotensin analogs as precursor drug candidates to treat schizophrenia. In addition to biological activity, the peptide structures have been optimized for cell transportation and solubility. Together with its sister company, Baltic Technology Development, Ltd., Molcode has also developed mimetics of neurotrophic factors (GDNF, BDNF, artemin) that are highly interesting as possible novel drug candidates against CNS diseases (Parkinson's, Alzheimer's, ALS) and neuropathic pain. The developments are in progress from discovery to late preclinical phases.

Gene silencing. Together with its sister company, Baltic Technology Development, Ltd., Molcode has developed a pivotal artificial nuclease technology that can dramatically silence the expression of viral genes in mammalian cells. The artificial enzymes are based on oligonucleotide analogs containing specifically modified DNA bases and organic complexes of lanthanides. In contrast to conventional antisense technology, these compounds provide multiple turnover, are non-toxic and therapeutically effective at low nanomolar concentrations. The proof-of-principle of efficient gene silencing of all classes of DNA and RNA viruses has been demonstrated. The developments based on this technology are entering Phase 1 clinical studies against Hepatitis C virus.

Development of small molecule antagonists of TrkA (PDF)
New antivirals against Hepatitis C (PDF)
Novel gene silecing technology (PDF)
Neurotrophic factor mimetics as drug candidates against neurological diseases (PDF)
Development of small molecule agonists of TrkB receptors (PDF)

MolCode, Ltd. | Ahtri 8, 10151 Tallinn, Estonia | Phone: +372 7 371 536, Fax: +372 7 371 535